Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-49.0,  H5N1 Influenza All participants (vaccinees, household contacts, and intimate contacts) must meet all of the following 1. Age 18 to 49 years for vaccinees. Vaccinees may be >49 years of age at the time of booster vaccination. Age 18 to 65 years for household and intimate contacts. 2. Negative FDA-approved HIV test 3. Able to provide proof of identity to the acceptance of the Principal Investigator or designee during enrollment. 4. Available and willing to participate in follow-up visits and tests for the duration of the study, 5. Willing to have samples stored for future research. 6. Negative <=-HCG pregnancy test for females presumed to be of reproductive potential. 7. A female must meet one of the following 1. No reproductive potential because of menopause (one year without menses) or because of a hysterectomy, bilateral oophorectomy, or tubal ligation. or 2. Participant agrees to be heterosexually inactive or consistently practice contraception at least 21 days prior to enrollment and 28 days following vaccination. Acceptable methods of contraception the following condoms, male or female, with a spermicide diaphragm or cervical cap with spermicide contraceptive pills, Norplant, or Depo-Provera male partner has previously undergone a vasectomy for which there is documentation intrauterine device 8. Male participants must agree to practice abstinence or effective birth control for at least 21 days prior to enrollment and during the first 28 days following vaccination. The following apply only to vaccinees and not to household or intimate contacts: 1. Willing to receive HIV test results and abide by NIH guidelines for partner notification of positive HIV results. 2. Physical examination and laboratory results without clinically significant findings within the 8 weeks prior to enrollment. 3. Willing to avoid vaccination other than the study agent for 30 days prior to and 30 days after administration of the Ad4-H5-Vtn vaccine. 4. Safety Laboratory within 8 weeks prior to enrollment Hematopoietic: White blood cell count and Lymphocyte count +/ the normal limits for the NIH Clinical Center Platelet count of least 125,000/mm3 Hemoglobin >11.2 g/dL for females and >13.0 g/dL for males  A participant (vaccinees, household contacts, and intimate contacts) will be excluded if they have the following: 1. Any condition that, in the investigator's judgement, places the subject at undue risk by participating in the study. The following criterion applies to vaccinees and intimate contacts, but not to household contacts: 1. History of any prior disease or therapy which would affect immune or pulmonary function. 2. Prior malignancy, except curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. 3. History of radiation therapy or cytotoxic/cancer chemotherapy. 4. History of insulin-dependent diabetes mellitus. 5. Immunodeficiency or autoimmune disease. 6. Acute infection or a recent (within 6 months) history of chronic infection suggestive of immunodeficiency. 7. Taking any medication which may affect immune function, except participants may be taking low doses of nonprescription strength (including e.g. ibuprofen or aspirin) or acetaminophen. 8. Chronic respiratory disorders including asthma, emphysema, interstitial lung disease, pulmonary hypertension, recurrent pneumonia, or recent or ongoing respiratory tract infection. If a respiratory disorder is transient, defer immunization but do not the participant. 9. Active Hepatitis B or C infection, as indicated by the presence of Hepatitis B antigen or Hepatitis C virus (i.e. Hepatitis B or C positive serology with the presence of virus antigen or DNA. Ongoing viral replication will be confirmed by a Hepatitis B antigen or Hepatitis C viral load). 10. Female of child-bearing potential who is breast-feeding or planning pregnancy during the 28 days following vaccination. The following apply only to vaccinees and not to household or intimate contacts: 1. Any medical, psychiatric, or social condition, or occupational or other responsibility that, in the judgment of the investigator, would interfere with or serve as a contraindication to receipt of live virus vaccine, protocol adherence, or a participant s ability to give informed consent. 2. Psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years; disorder requiring lithium; or suicidal ideation occurring within five years prior to enrollment. 3. Participants that live in the same house or apartment with any of the following will be excluded An individual under 18 years of age An immunocompromised or immunosuppressed individual An individual with chronic respiratory disease A woman who is currently pregnant or planning a pregnancy during the period of immunization 4. Healthcare worker who has direct contact with immunodeficient, unstable patients, or pediatric patients. 5. Participants caring for children <36 months of age. Potential vaccinees with any household or intimate contact who cares for children <36 months of age will also be excluded. 6. Receipt of any of the following Antiviral medications within 30 days prior to vaccination Blood products within 120 days prior to HIV screening Immunoglobulin within 60 days prior to HIV screening Investigational research drugs or any other investigational agent that in the judgement of the PI might interact with the study vaccine within 30 days prior to initial study vaccine administration